

QUILT-88: NANT Pancreatic Cancer Vaccine in 3rd, 4th, & 5th Line Advanced Disease

Open-label, combination immunotherapy plus standard-of-care chemotherapy and SBRT for the treatment of locally advanced or metastatic pancreatic cancer


NCT04390399

Tara Seery¹, Chaitali Nangia¹, Heide McKean² Leonard Sender³, Sandeep Reddy³, Patrick Soon-Shiong³

QUILT-88

¹Hoag Cancer Center, Newport Beach, CA; ² Avera Cancer Institute, Sioux Falls, SD ³ ImmunityBio Inc. Culver City, CA

RATIONALE & TREATMENT SCHEDULE



U.S. Patent 11,071,774

ADVERSE EVENTS

Demographics	
Age	62 (24, 78)
Age ≥ 65	43%
M:F	57/43
ECOG ≥ 2	3%
Metastasis	93%


Grade ≥3 TR AEs (all others <5% incidence)	
Anemia	32%
Neutropenia	25%
Thrombocytopenia	13%
Fatigue	7%

Any Grade TE AE >20%	
Fatigue	64%
Chills	57%
Pyrexia	49%
Injection site reaction	40%
Anemia	62%
Neutropenia	23%
Decreased Appetite	36%
Vomiting	37%
Nausea	40%
Abdominal pain	32%
Diarrhea	30%
Constipation	27%
Dyspnea	29%
Edema	25%


KEY FINDINGS

- Nant Cancer Vaccine (NCV) **approximately doubled median OS** versus historical OS (Manax ASCO GI 2019) of 3 months after >2L
- In QUILT 88, median OS in **CA 19-9 < 4120 (median of all study subjects) n=40, was 6.9 months (95% CI: 5.7, 10.9)**
- 51/83 subjects, 61% (95% CI: 50.1, 71.9) exhibited disease control**
- 100%** of treatments were performed in the **outpatient** setting with acceptable toxicity

RESULTS



Overall Survival by Baseline CA19-9 Median (4120) ITT Population



Overall Survival ITT Population by Line of Therapy

Variable	3 rd Line Therapy (N = 41)	≥ 4 th Line Therapy (N = 42)	≥ 5 th Line Therapy (N = 22)	All ≥ 3 rd Line Therapy (N = 83)
Number of Deaths	31 (76%)	30 (71%)	13 (59%)	61 (73%)
Median Survival (months)	6.3	4.9	6.3	5.8
95% CI for the Median Survival	5.0, 7.2	3.2, 6.3	4.0, 15.2	4.9, 6.4

Overall Survival by Baseline CA19-9 Median (4120 IU/mL) ITT Population

Variable	Baseline CA19-9 < Median (4120) (N = 40)	Baseline CA19-9 ≥ Median (4120) (N = 41)	Log-rank P-value	Hazard Ratio (95% Confidence Interval)
Number of Deaths	24 (60%)	37 (90%)		
Median Survival (months)	6.9	3.9	<.001	3.0 (1.73, 5.10)
95% CI for the Median Survival	5.7, 10.9	2.8, 5.2		

CI = Confidence Interval.
Note: Subjects who were alive at the end of follow-up were censored at the last known date alive.

